Toledo Community Hospital Oncology Program (TCHOP) seeks funding to continue its ongoing Community Clinical Oncology Program to provide the most advanced knowledge and technology currently achieved through cancer prevention and treatment trials to both urban and rural communities throughout its catchment area. Since receiving original funding in 1982, the Toledo CCOP has grown to include 17 components and institutions within the consortium. The catchment area has expanded to include Northwest and Northeast Ohio, Southeast Michigan and Eastern Virginia. The Toledo CCOP's strengths are: 25 years of positively contributing to National Cancer Institute's success in community-based research;a strong record of accrual to both treatment and prevention/control trials;experienced and effective organizational management;dedicated physician participation;and leadership in scientific and committee activities with the cooperative groups. TCCOP has in place adequate plans and support personnel to follow-up participants enrolled in large prevention trials. Finally, TCCOP's improved data management and communication infrastructure will support increased accrual while maintaining appropriate standards in an effective efficient manner that assures quality and TCCOP's ability to meet requirements of the Research Base and Federal entities. With funding through the National Cancer Institute Community Clinical Oncology Program (U10), TCCOP will persist in contributing to the discovery of treatment options for people who have been devastated by a cancer diagnosis.

Public Health Relevance

Clinical research trials are necessary to advance and improve treatment outcomes of patients diagnosed with cancer. The growing body of knowledge from previous clinical cancer research trials has promoted healthy lifestyles to prevent or postpone the onset of cancer. However, many questions remain unanswered which require community participation in cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035415-28
Application #
8092784
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
Whitman, Cynthia B
Project Start
1983-09-15
Project End
2015-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
28
Fiscal Year
2011
Total Cost
$820,654
Indirect Cost
Name
Toledo Community Hospital Oncology Prog
Department
Type
DUNS #
840301183
City
Toledo
State
OH
Country
United States
Zip Code
43617
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Tan, A D; Novotny, P J; Kaur, J S et al. (2016) QOL and Survival Comparisons by Race in Oncology Clinical Trials. J Cancer Clin Oncol 2:
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43
Dueck, A C; Singh, J; Atherton, P et al. (2015) Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 26:1971-7

Showing the most recent 10 out of 130 publications